AIDS landmark trials

Sexually transmitted diseases Main Page
	AIDS Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating AIDS from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
HIV Opportunistic Infections
HIV Coinfections
HIV and Pregnancy
HIV Infection in Infants
Diagnosis
Diagnostic Study of Choice
AIDS Case Definition
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Nutrition
Drug Resistance
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies HIV Vaccine
Case Studies
Case #1
AIDS landmark trials On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of AIDS landmark trials All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on AIDS landmark trials
CDC on AIDS landmark trials
AIDS landmark trials in the news
Blogs on AIDS landmark trials
Directions to Hospitals Treating AIDS
Risk calculators and risk factors for AIDS landmark trials

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ujjwal Rastogi, MBBS

Overview

Clinical trials are a set of procedures in medical research and drug development that are conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g., drugs, diagnostics, devices, therapy protocols). Several trials have been conducted till date that have immense contribution.

Landmark Trials

Clinical Trials of Non-nucleoside Reverse Transcriptase Inhibitors

1. Efavirenz and Nevirapine (2NN study) (2004)^[1]

Purpose : It was a randomised comparison of the non-nucleoside reverse-transcriptase inhibitors (NNRTI) nevirapine and efavirenz.
Study Design: Randomised trial

2. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO) (2011) ^[2]

Purpose : Interventional
Study Design: Randomised, double-blind, double-dummy, active-controlled trial.

Registeries

HIV drug resistance database

References

↑ van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM (2004). "Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study". Lancet. 363 (9417): 1253–63. doi:10.1016/S0140-6736(04)15997-7. PMID 15094269. Retrieved 2012-02-21. Unknown parameter |month= ignored (help)
↑ Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K (2011). "Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial". Lancet. 378 (9787): 238–46. doi:10.1016/S0140-6736(11)60936-7. PMID 21763936. Retrieved 2012-02-22. Unknown parameter |month= ignored (help)

Template:WH Template:WS

[pmid15094269-1] van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM (2004). "Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study". Lancet. 363 (9417): 1253–63. doi:10.1016/S0140-6736(04)15997-7. PMID 15094269. Retrieved 2012-02-21. Unknown parameter |month= ignored (help)

[pmid21763936-2] Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K (2011). "Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial". Lancet. 378 (9787): 238–46. doi:10.1016/S0140-6736(11)60936-7. PMID 21763936. Retrieved 2012-02-22. Unknown parameter |month= ignored (help)

[1]

[2]